Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer is a research paper published in Cancer Chemotherapy and Pharmacology (2025). On theSindex it has a DataRank of 0.241. It has been cited 4 times, with 4 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.241
From this paper's citation signal
Citation Network Contribution
0
From 0 citing papers with measurable signal
This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.
Learn more about DataRank methodology →National Cancer Institute
Grant: R50CA211241
National Cancer Institute
Grant: R01CA237027
U.S. Department of Defense
Grant: PC220137
Prostate Cancer Foundation (PCF) Challenge Award
Grant: 2022CHAL3788
NCI NIH HHS
Grant: P30 CA047904
NCI NIH HHS
Grant: R01 CA240290
AbbVie
Fields of Study
MeSH Terms
Keywords